Intravenous γ‐Globulin Treatment in Kawasaki Disease

Publisher Website
Google Scholar
Abstract
A multicenter randomized controlled study was carried out to assess the effectiveness of different, doses and kinds of γ‐globulin in Kawasaki disease. Gamma globulin lowered the incidence of coronary artery abnormalities. The effect of γ‐globulin was dose dependent. The intact type was more effective than the pepsin treated type. To establish the indications for γ‐globulin, a study was made of patients who received neither γ‐globulin nor indomethacin and who, within nine days of onset of illness, satisfied at least four of the following criteria: (1) WBC: more than 12,000/mm; (2) platelet count: less than 35×104γmm; (3) CRP: more than 3 +; (4) Hct: less than 35%; (5) albumin: less than 3.5 g/dl (6) age: 12 months or less; (7) male sex. This prospective study is continuing. Of 143 children, 73.4% received γ‐globulin, and only two demonstrated small dilatations of the coronary arteries in children who did not receive γ‐globulin. These guidelines seem satisfactory to establish the indications for γ‐globulin in Kawasaki disease.

This publication has 1 reference indexed in Scilit: